BIOINFORMATICS ORIGINAL PAPER

Vol. 29 no. 16 2013, pages 2004â€“2008
doi:10.1093/bioinformatics/btt307

Systems biology

Advance Access publication May 29, 2013

Drugâ€“target interaction prediction through domain-tuned
network-based inference
Salvatore Alaimo1, Alfredo Pulvirenti2,*, Rosalba Giugno2 and Alfredo Ferro2
1Department of Mathematics and Computer Science and 2Department of Clinical and Molecular Biomedicine,
University of Catania, Catania, Italy
Associate Editor: Martin Bishop

ABSTRACT
Motivation: The identification of drugâ€“target interaction (DTI) repre-
sents a costly and time-consuming step in drug discovery and design.
Computational methods capable of predicting reliable DTI play an im-
portant role in the field. Recently, recommendation methods relying on
network-based inference (NBI) have been proposed. However, such
approaches implement naive topology-based inference and do not
take into account important features within the drugâ€“target domain.
Results: In this article, we present a new NBI method, called domain
tuned-hybrid (DT-Hybrid), which extends a well-established recom-
mendation technique by domain-based knowledge including drug
and target similarity. DT-Hybrid has been extensively tested using
the last version of an experimentally validated DTI database obtained
from DrugBank. Comparison with other recently proposed NBI meth-
ods clearly shows that DT-Hybrid is capable of predicting more
reliable DTIs.
Availability: DT-Hybrid has been developed in R and it is available,
along with all the results on the predictions, through an R package at
the following URL: http://sites.google.com/site/ehybridalgo/.
Contact: apulvirenti@dmi.unict.it
Supplementary information: Supplementary data are available at
Bioinformatics online.

Received on March 26, 2013; revised on May 11, 2013; accepted on
May 23, 2013

1 INTRODUCTION

Detecting and verifying new connections among drugs and tar-
gets is a costly process. From a historical point of view, the
pharmaceutical chemistâ€™s approach has been commonly focused
on the development of compounds acting against particular
families of â€˜druggableâ€™ proteins (Yildirim et al., 2007). Drugs
act by binding to specific proteins, hence changing their bio-
chemical and/or biophysical activities, with many consequences
on various functions. Furthermore, because proteins operate as
part of highly interconnected cellular networks (i.e. the interac-
tome networks), the â€˜one gene, one drug, one diseaseâ€™ paradigm
has been challenged in many cases (Hopkins, 2008). For this
reason, the concept of polypharmacology has been raised for
those drugs acting on multiple targets rather than a single one
(Hopkins, 2008). These polypharmacological features of drugs
bring a wealth of knowledge and enable us to understand drug

*To whom correspondence should be addressed.

side effects or find their new uses, namely, drug repositioning
(Ashburn and Thor, 2004; Boguski et al., 2009).

Nevertheless, many interactions are still unknown, and given
the significant amount of resources needed for in situ experimen-
tation,
it is necessary to develop algorithmic methodologies
allowing the prediction of new and significant relationships
among elements interacting at the process level.

In the literature, several computational tools have been pro-
posed to afford the problem of DTI prediction and drug
repositioning.

Traditional methods rely either on ligand-based or receptor-
based approaches. Among ligand-based methods, we can cite
quantitative structure-activity relationships, and a similarity
search-based approach (Gonzalez-Daz et al., 2011; Keiser
et al., 2007). On the other hand, receptor-based methods, such
as reverse docking, have also been applied in drugâ€“target (DT)
binding affinity prediction, DTI prediction and drug reposition-
ing (Ashburn and Thor, 2004; Li et al., 2006; Xie et al., 2011).
However, the latter have the shortcoming that cannot be used for
targets whose 3D structures are unknown.

Recently, much attention has been devoted to network-based
and phenotype-based approaches. Most of these methods rely on
the successful idea of using bipartite graphs.

In Yildirim et al. (2007), a bipartite graph linking US Food
and Drug Administration-approved drugs to proteins by DT
binary associations is exploited. Campillos et al. (2008) identified
new DTIs using side effect similarity.

Iorio et al. (2010) make use of transcriptional responses, pre-
dicted and validated new drug modes of action and drug repos-
itioning. Recently, Dudley et al. (2011) and Sirota et al. (2011)
have presented drug repositioning methods exploiting public
gene expression data. Furthermore, Yamanishi et al. (2008) de-
veloped a bipartite graph learning method to predict DTI by
integrating chemical and genomic data.

Cheng et al. (2012) present a technique based on network-based
inference (NBI) implementing a naive version of the algorithm
proposed by Zhou et al. (2007). All these results clearly show
the good performance of this approach. On the other hand, know-
ledge about drug and protein domain is not properly exploited.

van Laarhoven et al. (2011) use a machine learning method
starting from a DTI network to predict new ones with high ac-
curacy. The calculation of the new interactions is done through
the regularized least squares algorithm. The regularized least
squares algorithm is trained using a kernel (GIPâ€”Gaussian
interaction profile) that summarizes the information in the net-
work. The authors developed variants of the original kernel by

ÃŸ The Author 2013. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial
re-use, please contact journals.permissions@oup.com

taking into account chemical and genomic information. This im-
proved the accuracy, in particular for small datasets.

Chen et al. (2012) introduced their Network-based Random
Walk with Restart on the Heterogeneous network (NRWRH)
algorithm predicting new interactions between drugs and targets
by means of a model based on a random walk with a restart in a
â€˜heterogeneousâ€™ network. The model is constructed by extending
the network of DTI interactions with drugâ€“drug and proteinâ€“pro-
tein similarity networks. This methodology shows excellent per-
formance
its
disadvantage is due to its random nature, mainly caused by the
initial probabilities selection.

in predicting new interactions. However,

Mei et al.

(2013) proposed the Bipartite Local Model-
Interaction-profile Inferring (BLM-NII) algorithm. Interactions
between drugs and targets are deduced by training a classifier
(i.e. support vector machine or regularized least square). This is
achieved by exploiting interaction information, drug and target
similarities. This classifier is appropriately extended to include
knowledge on new drug/target candidates. This is used to predict
the new target probability of a specific drug. The algorithm is
highly reliable in predicting interactions between new drug/target
candidates. On the other hand, its capability of training several
distinct classifiers to obtain the final model is not strong enough.
In this present article, we propose a novel method called do-
main tuned-hybrid (DT-Hybrid). It extends the NBI algorithm
proposed in Zhou et al. (2007) and applied in Cheng et al.
(2012) by adding application domain knowledge. Similarity
among drugs and targets is plugged into the model. Despite its
simplicity, the technique provides a complete and functional
framework for in silico prediction of drug and target relationships.
To demonstrate the reliability of the method, we conducted a wide
experimental analysis using four benchmark datasets drawn from
DrugBank. We compared our method with the one proposed by
Chen et al., 2012. The experiments clearly show that DT-Hybrid
overcomes the problems shown by the naive NBI algorithm, and it
is capable of producing higher quality predictions.

2 METHODS

f

2.1 Algorithm
The method we propose is based on the recommendation technique pre-
sented by Zhou et al. (2007) and extended by Zhou et al. (2010). Let
X Â¼ x1, x2, . . . , xm
g be a set of small molecules (i.e. biological com-
pounds, molecules), and T Â¼ t1, t2, . . . , tn
g a set of targets (i.e. genes,
proteins); the X-T network of interactions can be described as a bipartite
. A link between xi and tj
graph G X, T, E
 	
is drawn in the graph when the structure xi is associated with the target tj.
The network can be represented by an adjacency matrix A Â¼ aji
nm,
where aji Â¼ 1 if xi is connected to tj; otherwise, aji Â¼ 0.

	
Ãž where E Â¼ eij : xi 2 X, tj 2 T



f

Ã°

Zhou et al. (2010) proposed a recommendation method based on the
bipartite network projection technique implementing the concept of re-
sources transfer within the network. Given the bipartite graph defined
above, a two-phase resource transfer is associated with one of its projec-
tions: at the beginning, the resource is transferred from nodes belonging
to T to those in X, and subsequently the resource is transferred back to
	
the T nodes. This process allows us to define a technique for the calcu-
lation of the weight matrix (W Â¼ wij
X
nn) in the projection as follows:
m
Ã°1Ãž



wij Â¼ 1
Ã°
  i, j

Ãž

ailajl
k xlÃ°
Ãž,

lÂ¼1

Drugâ€“target interaction prediction

Table 1. List of algorithms with the associated   functions

Algorithm

(1)
(2)
(3)
(4)

NBI (Zhou et al., 2007)
HeatS (Zhou et al., 2010)
Hybrid NÃ¾H (Zhou et al., 2010)
DT-Hybrid

  Function
  
Ãž Â¼ k tj
  
Ãž Â¼ k tiÃ° Ãž

  
Ãž Â¼ k tiÃ° Ãž1 k tj
Ãž Â¼ k tiÃ° Ãž1 k tj

Ã°
  i, j
Ã°
  i, j
Ã°
  i, j
Ã°
  i, j




=sij



where   determines how the distribution of resources takes place in the
second phase, and k xÃ° Ãž is the degree of the x node in the bipartite network.
By varying the   function, we obtain the following algorithms (Table 1):
 NBI, introduced by Zhou et al. (2007) and used by Cheng et al.
(2012) for the prediction of the interactions between drugs and
proteins;

 HeatS, introduced by Zhou et al. (2010);
 Hybrid NÃ¾H, introduced by Zhou et al. (2010), in which the func-
tions defined in NBI and HeatS are combined in connection with a
parameter called ;

 DT-Hybrid, introduced here, is an enhanced version of the Hybrid
algorithm in which previous domain-dependent biological know-
ledge is plugged into the model through a similarity matrix.

Ã°2Ãž

Given the weight matrix W and the adjacency matrix A of the bipartite
is possible to compute the recommendation matrix

it

 	
network,
R Â¼ rij

nm by the product:

R Â¼ W  A:



 



For each xi

Ri Â¼ tj, rji

	
in X,
its recommendation list is given by the set
j aji Â¼ 0
, where rji is the â€˜scoreâ€™ of recommending tj to xi.
This list is then sorted in a descending order with respect to the score
because the higher elements are expected to have a better interaction with
the corresponding structure.

Notice that the method described above does not make use of any
previous biological knowledge of the application domain. Here we pro-
pose the DT-Hybrid algorithm, which extends the recommendation
model by introducing: (i) similarity between small molecules (i.e. molecu-
lar compounds), and (ii) sequence similarity between targets.

nn be the target similarity matrix [i.e. either BLAST bits
scores (Altschul et al., 1990) or Smith-Waterman local alignment scores
(Smith and Waterman, 1981)]. This information can be taken into ac-
Ãž defined as in row 4 of Table 1.
count by using equation (1) with   i, j
Including structural similarity requires more effort. Therefore, it is neces-
sary to manipulate such information to obtain a variant of the S matrix,
and simplify the computation of the equation (1).

Ã°

 	
Let S Â¼ sij

mm

be the structure similarity matrix [i.e. SIMCOMP

n o
similarity score (Hattori et al., 2003) in the case of compounds]. It is
possible to obtain a matrix S2 Â¼ s00
ij describes
similarity between ti and tj based on the common interactions in the

(where each element s00

nn

ij

n o
Let S1 Â¼ s0

ij

network weighted by compound similarity) by putting:



 

P
P
m
kÂ¼1
m
kÂ¼1

P

P
lÂ¼1 ailajks0
lk
m
lÂ¼1 ailajk

 

m

ij Â¼
s00

:

Ã°3Ãž

This matrix can be linearly combined with the target similarity matrix S,
Ã°4Ãž

SÃ°1Ãž Â¼ S Ã¾ 1   

Ã°

ÃžS2,

where  is a tuning parameter.

This additional biological knowledge yields faster computation and
higher numerical precision. The matrix defined by equation (4) in

2005

S.Alaimo et al.

connection with equations (1) and (2) allows the prediction of recommen-
dation lists.

2.2 Datasets and benchmarks
We evaluated our method using four datasets (Cheng et al., 2012) con-
taining experimentally verified interactions between drugs and genes. We
analyzed the performances of NBI [equation (1) using  (i,j) in Table 1,
row 1], Hybrid [equation (1) using  (i,j) in Table 1, row 3] and DT-
Hybrid [equation (1) using  (i,j) in Table 1, row 4].

The datasets were built by grouping all possible interactions between
genes and drugs (DTI) based on their main gene types: enzymes, ion
channels, G-protein coupled receptors (GPCRs) and nuclear receptors
(Table 2). The following similarity measures have been used:
(i)
SIMCOMP 2D chemical similarity of drugs (Hattori et al., 2003), and
(ii) Smith-Waterman sequence similarity of genes (Smith and Waterman,
1981).

Similarities have been normalized according to Yamanishi et al. (2008):
Ã°5Ãž

Ãž Â¼

p

Snorm i, j

Ã°

:

Ãž

ï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒï¬ƒ
Ã°
S i, j
Ãž  S j, j
Ã°
Ãž
S i, i

Ã°

Results are evaluated by combining the methods presented by Zhou
et al. (2010) and Cheng et al. (2012). More precisely, we applied a 10-fold
cross-validation and repeated the experiments 30 times.

Notice that, the random partition used in the cross-validation could
cause isolation of nodes in the network on which the test is performed.
Because all the tested algorithms are capable of predicting new inter-
actions only for drugs and targets for which we already have some infor-
mation, we computed the partition so that for each node, at least one link
to the other nodes remains in the test set.

According to Zhou et al. (2010), the following four metrics were con-
sidered: precision and recall enhancement, recovery, personalization and
surprisal.
Precision and Recall Enhancement, eP LÃ° Ãž and eR LÃ° Ãž. Quality is mea-
sured in terms of the top L elements in the recommendation list of each
biological structure. Let Di be the number of deleted interactions re-
covered for drug i, and let DiÃ°LÃž be its position in the top L places of
iâ€™s recommendation list. The average precision and recall for the predic-
tion process can be computed as follows:
X
m0

P LÃ°

Ãž Â¼ 1
m0

Di LÃ° Ãž
L

,

Ã°6Ãž

iÂ¼1
X
m0

iÂ¼1

R LÃ° Ãž Â¼ 1
m0

Di LÃ° Ãž
Di

,

Ã°7Ãž

where m0 is the number of structures with at least one deleted link. A
better perspective can be obtained by considering these values within
random models Prand LÃ° Ãž and Rrand LÃ° Ãž.

Table 2. Description of the dataset: number of biological structures, tar-
gets and interactions together with a measure of sparsity

Ã°

If

the structure i has a total of Di deleted interactions,

then
Ãž  Di=n [given that n  k iÃ° Ãž]. Consequently,
rand LÃ° Ãž Â¼ Di= n   k iÃ° Ãž
Pi
Ãž Â¼ D=n  m, where D is
averaging for all structures we obtain Prand LÃ°
the number of links in the test set. On the other hand, the average
number of
is given by
LDi= n   k iÃ° Ãž
structures,
Rrand LÃ° Ãž Â¼ L=n. Given these random models, it is possible to compute
the precision and recall enhancement as follows:

links deleted in the first L positions
Ãž  LDi=n. Again by averaging for all

Ã°

eP LÃ° Ãž Â¼ P LÃ° Ãž

Prand LÃ° Ãž Â¼ P LÃ°

Ãž  n  m

D

,

eR LÃ° Ãž Â¼ R LÃ° Ãž

Rrand LÃ° Ãž Â¼ R LÃ° Ãž  n

L

:

Ã°8Ãž

Ã°9Ãž

Finally, as opposed to the recommendation on social systems, the three
other metricsâ€”recovery, personalization and surprisalâ€”are not so sig-
nificant in drugâ€“target systems. For this reason, we report the details of
such metrics (their definitions together with the experimental results), just
for completeness, in the Supplementary Materials.

3 RESULTS

In this article, we propose a method called DT-Hybrid, which
extends NBI (Cheng et al., 2012; Zhou et al., 2007) and the
Hybrid (Zhou et al., 2010) algorithms by integrating previous
domain-dependent knowledge. Experiments show that this ex-
tension improves both algorithms in terms of prediction of new
biologically significant interactions. In the supporting materials,
we report a comprehensive analysis of DT-Hybrid and Hybrid,
together with their behavior varying the  (only for DT-Hybrid)
and  parameters. Table 3 illustrates the result of comparing
NBI, Hybrid and DT-Hybrid in terms of precision and recall
enhancement. DT-Hybrid clearly outperforms both NBI and
Hybrid in recovering deleted links. It is important to point out
that hybrid algorithms are able to significantly improve recall
(eR) measuring the prediction ability of recovering existing inter-
actions in a complex network. Figure 1 illustrates the receiver
operating characteristic (ROC) curves calculated over the com-
plete DrugBank dataset. Simulations were executed 30 times, and
the results were averaged to obtain a performance evaluation.
Experiments show that all three techniques have a high true-
positive rate against a low false-positive rate. However, hybrid
algorithms provided better performance than NBI. In particular,
Table 3 clearly shows an increase of the average areas under the
ROC curves (AUC) in the complete dataset (a detailed analysis
can be found in the supporting materials section). This indicates
that hybrid algorithms improve the ability of discriminating

Table 3. Comparison between DT-Hybrid, Hybrid and NBI

Dataset

Structures

Targets

Interactions

Sparsity

Enzymes
Ion channels
GPCRs
Nuclear receptors

445
210
223
54

664
204
95
26

2926
1476
635
90

Complete DrugBank

4398

3784

12 446

0.0099
0.0344
0.0299
0.0641

0.0007

Note: The sparsity is obtained as the ratio between the number of known inter-
actions and the number of all possible interactions.

Algorithm

NBI
Hybrid
DT-Hybrid

eP 20Ã°
Ãž

538.7
861.3
1141.8

eR 20Ã°
Ãž

55.0
85.7
113.6

AUC 20Ã°
Ãž

0.9619 0.0005
0.9976 0.0003
0:9989  0:0002

Note: For each algorithm the complete DrugBank dataset was used to compute the
precision and recall metrics, and the average area under ROC curve (AUC). The
parameters used to obtain the following results are  Â¼ 0:7, and  Â¼ 0:8. Values are
obtained using the top-20 predictions. Bold values represents best results.

2006

Drugâ€“target interaction prediction

Fig. 1. Comparison between DT-Hybrid, Hybrid, and NBI by means of receiver operating characteristic (ROC) curves, computed for the top-L places of
the recommendation lists, which were built on the complete DrugBank dataset

Table 4. Comparison of DT-Hybrid, Hybrid, and NBI through the precision and recall enhancement metric, and the average area under ROC curve
(AUC) calculated for each of the four datasets listed in Table 2

Precision enhancement [eP 20Ã°

Ãž]

Recall enhancement [eR 20Ã°
Ãž]

Area Under Curve for the top-20 predictions [AUC 20Ã°
Ãž]

Data set

NBI

Hybrid

DT-Hybrid

NBI Hybrid DT-Hybrid NBI

Hybrid

DT-Hybrid

Enzymes
Ion channels
GPCRs
Nuclear receptors

103.3
22.8
27.9
28.9

104.6
25.4
33.7
31.5

228.3
37.0
50.4
70.2

19.9
9.1
7.5
0.3

20.9
9.7
8.8
1.3

32.9
10.1
5.0
1.3

0:9789  0:0007
0:9320  0:0046
0:9690  0:0015
0:9944  0:0007

0:9982  0:0002
0:9929  0:0008
0:9961  0:0007
0:9986  0:0004

0:9995  0:0001
0:9973  0:0006
0:9995  0:0006
1:0000  0:0000

Note: The results were obtained using the optimal values for  and  parameters as shown in the supporting materials. We set for both Hybrid and DT-Hybrid  Â¼ 0:5.
Concerning the  parameter, we have the following setting: enzymes  Â¼ 0:4; ion channels  Â¼ 0:3; GPCRs  Â¼ 0:2; nuclear receptors  Â¼ 0:4. Bold values represents best results.

known links from predicted ones. The increase of the AUC
values for the DT-Hybrid algorithm demonstrates that adding
biological information to prediction is a key choice to achieve
significant results. Table 4 demonstrates that exploiting biolo-
gical information leads, in most cases, to a significant increase
of the adjusted precision and recall. Figure 2 illustrates the ROC
curves calculated on the enzymes, ion channels, GPCRs, and
nuclear receptor datasets using the top-30 predictions. Finally,
it can be asserted that adding similarity makes prediction more
reliable than an algorithm, such as NBI, which applies only net-
work topology to score computation. Indeed, using only known
interactions of a new structure without any target information
makes it impossible to predict new targets for this drug. This
weakness is a problem for all methods based on recommendation
techniques. The introduction of new biological structures is
equivalent to the addition of isolated nodes in the network,
whose weight, based on the equation (1), is always zero. Such
a weight, ultimately, leads to the impossibility of obtaining a
prediction for this new molecule.

Another important feature of the DT-Hybrid algorithm that
we would like to highlight is its ability of increasing performance
by keeping computational complexity acceptable. The asymp-

totic complexity of the NBI algorithm is O n2m
, whereas
that of DT-Hybrid is O n2 m Ã¾ m2
. However, parallelization
and optimization techniques can be easily applied to speed
computation.



 

 



 

We investigated the dependence of DT-Hybrid prediction
quality with respect to the  and  parameters (see the support-
ing materials for the details). Results show that we cannot dis-
cern a law that regulates the behavior of the metrics based on the
values of these parameters. They depend heavily on the specific
characteristics of each dataset, and therefore require a priori ana-
lysis to select the best ones. In the reported results, we made such
analysis before to run our experiments to establish the param-
eters yielding the best results in terms of precision and recall
enhancement.

Finally, notice that our analysis has shown an increase in the
precision, recall and AUC, neglecting other metrics, such as re-
covery, personalization and surprisal. This was done because the
latter measure only the capability of analyzing the structure of an
interaction network without evaluating the biological signifi-
cance of predictions.

4 CONCLUSION

DT-Hybrid is a technique proposed for the prediction of
new interactions between small molecules. Thanks to the
domain-dependent additional knowledge, it clearly outperforms
the NBI algorithm for DTI prediction. DT-Hybrid integrates
biological knowledge and the bipartite interaction network into
a unified framework. This yields high quality and consistent
interaction prediction, allowing a speedup of the experimental

2007

S.Alaimo et al.

Fig. 2. Comparison between DT-Hybrid, Hybrid and NBI by means of receiver operating characteristic (ROC) curves, computed for the top-30 places
of the recommendation lists, which were built on the four datasets (enzymes, ion channels, GPCRs and nuclear receptors)

verification activity. Finally, thanks to the hybrid approach, the
algorithm overcomes numerical instability that we experienced in
the NBI algorithm in presence of particular datasets (i.e. highly
sparse).

Funding: The publication costs for this article were funded by PO
grant - FESR 2007-2013 Linea di
intervento 4.1.1.2, CUP
G23F11000840004.

Conflict of Interest: None declared.

REFERENCES

study of G3PDH protein from Trichomonas gallinae. J. Proteome Res., 10,
1698â€“1718.

Hattori,M. et al. (2003) Development of a chemical structure comparison method
for integrated analysis of chemical and genomic information in the metabolic
pathways. J. Am. Chem. Soc., 125, 11853â€“11865.

Hopkins,A. (2008) Network pharmacology: the next paradigm in drug discovery.

Nat. Chem. Biol., 4, 682â€“690.

Iorio,F. et al. (2010) Discovery of drug mode of action and drug repositioning from

transcriptional responses. Proc. Natl Acad. Sci. USA, 107, 14621â€“14626.

Keiser,M. et al. (2007) Relating protein pharmacology by ligand chemistry. Nat.

Biotechnol., 25, 197â€“206.

Li,H. et al. (2006) TarFisDock: a web server for identifying drug targets with dock-

ing approach. Nucleic Acids Res., 34 (Suppl. 2), W219â€“W224.

Mei,J. et al. (2013) Drug-target interaction prediction by learning from local infor-

mation and neighbors. Bioinformatics, 29, 238â€“245.

Sirota,M. et al. (2011) Discovery and preclinical validation of drug indications using

Altschul,S.F. et al. (1990) Basic local alignment search tool. J. Mol. Biol., 215,

compendia of public gene expression data. Sci. Transl. Med., 3(96ra), 77.

403â€“410.

Smith,T.F. and Waterman,M.S. (1981) Identification of common molecular subse-

Ashburn,T. and Thor,K. (2004) Drug repositioning: identifying and developing new

quences. J. Mol. Biol., 147, 195â€“197.

uses for existing drugs. Nat. Rev. Drug Discov., 3, 673â€“683.

van Laarhoven,T. et al. (2011) Gaussian interaction profile kernels for predicting

Boguski,M. et al. (2009) Repurposing with a difference. Science, 324, 1394â€“1395.
Campillos,M. et al. (2008) Drug target identification using side-effect similarity.

Science, 321, 263â€“266.

Chen,X. et al. (2012) Drug-target interaction prediction by random walk on the

heterogeneous network. Mol. Biosyst., 6, 1970â€“1978.

drugâ€“target interaction. Bioinformatics, 27, 3036â€“3043.

Xie,L. et al. (2011) Drug discovery using chemical systems biology: weak inhibition
of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS
Comput. Biol., 7, e1002037.

Yamanishi,Y. et al. (2008) Prediction of drugâ€“target interaction networks from the

Cheng,F. et al. (2012) Prediction of drug-target interactions and drug repositioning

integration of chemical and genomic spaces. Bioinformatics, 24, i232â€“i240.

via network-based inference. PLoS Comput. Biol., 8, e1002503.

Dudley,J. et al. (2011) Computational repositioning of the anticonvulsant topira-

Yildirim,M. et al. (2007) Drug-target network. Nat. Biotechnol., 25, 1119â€“1126.
Zhou,T. et al. (2007) Bipartite network projection and personal recommendation.

mate for inflammatory bowel disease. Sci. Transl. Med., 3, 96ra76.

Phys. Rev. E Stat. Nonlin. Soft Matter Phys., 76, 046115.

Gonzalez-Daz,H. et al. (2011) Mind-best: web server for drugs and target discovery;
design, synthesis, and assay of MAO-B inhibitors and theoreticalâ€“experimental

Zhou,T. et al. (2010) Solving the apparent diversity-accuracy dilemma of recom-

mender systems. Proc. Natl Acad. Sci. USA, 107, 4511â€“4515.

2008

